Literature DB >> 33706032

Insights from participant engagement with the tuberculosis treatment support tools intervention: Thematic analysis of interactive messages to guide refinement to better meet end user needs.

Hannah Milligan1, Sarah J Iribarren2, Cristina Chirico3, Hugo Telles3, Rebecca Schnall4.   

Abstract

BACKGROUND: Tuberculosis (TB) is a largely curable disease, yet it remains one of the top ten causes of death globally. In response to known challenges to completing the long course of TB treatment, our study team developed the TB treatment support tools (TB-TSTs). The mobile application (app) is comprised of the following main components: 1) tracks treatment progress, 2) provides disease tailored information, 3) interactive communication between patients and treatment supporters, and 4) is linked with a direct adherence drug metabolite test.
OBJECTIVE: The objective of this study was to analyze the interactive communication between the patients and the treatment supporter during the TB-TSTs pilot testing to identify issues and guide intervention refinement.
METHODS: We used mixed methods to analyze the interactive communication data. The study was conducted at a pulmonary disease specialized hospital in Argentina. Of the 42 study participants enrolled in the pilot study, 21 were randomly assigned to use the TB-TSTs for 6-months during their TB treatment. The treatment supporter was a registered nurse from the regional level of the National TB program. We conducted thematic and content analysis of the messages in their original language, Spanish. We assessed the themes over time and by whom initiated the messages.
RESULTS: There were 2561 individual messages sent between the participants and treatment supporter. We identified 19 main themes: 7 were participant and 12 were treatment supporter initiated. Participant themes included missed report rationale, arranging in-person meeting, intervention support, TB treatment progress, disease/treatment questions, side effects and additional support. Treatment supporter themes included missed report inquiry, arranging in-person meeting, introduction and instructions, check-in's, positive reinforcement, treatment progress inquiry, test-strip issues, intervention orientation, initial side-effect check in, follow-up on side effects and photo quality issues. Messages and themes decreased over time with most occurring within the first 2 months of treatment.
CONCLUSIONS: Although there was a decrease in the number of messages and the theme types over the 6-month study participation, treatment adherence support remained needed throughout. Potential solutions are suggested for the main issues and recommendations are being used to guide refinement.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Digital health; Treatment adherence; Treatment support; Tuberculosis

Mesh:

Year:  2021        PMID: 33706032     DOI: 10.1016/j.ijmedinf.2021.104421

Source DB:  PubMed          Journal:  Int J Med Inform        ISSN: 1386-5056            Impact factor:   4.730


  3 in total

1.  Patient-centered mobile tuberculosis treatment support tools (TB-TSTs) to improve treatment adherence: A pilot randomized controlled trial exploring feasibility, acceptability and refinement needs.

Authors:  Sarah J Iribarren; Hannah Milligan; Cristina Chirico; Kyle Goodwin; Rebecca Schnall; Hugo Telles; Alejandra Iannizzotto; Myrian Sanjurjo; Barry R Lutz; Kenneth Pike; Fernando Rubinstein; Marcus Rhodehamel; Daniel Leon; Jesse Keyes; George Demiris
Journal:  Lancet Reg Health Am       Date:  2022-06-10

2.  Acceptance of an Informational Antituberculosis Chatbot Among Korean Adults: Mixed Methods Research.

Authors:  Agnes Jihae Kim; Jisun Yang; Yihyun Jang; Joon Sang Baek
Journal:  JMIR Mhealth Uhealth       Date:  2021-11-09       Impact factor: 4.773

3.  Living with tuberculosis: a qualitative study of patients' experiences with disease and treatment.

Authors:  Juliet Addo; Dave Pearce; Marilyn Metcalf; Courtney Lundquist; Gillian Thomas; David Barros-Aguirre; Gavin C K W Koh; Mike Strange
Journal:  BMC Public Health       Date:  2022-09-10       Impact factor: 4.135

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.